No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
作者: Cristina RebordosaEline HoubenKristina LaugesenUlrich BothnerJukka MontonenJaume AguadoJetty A. OverbeekVera EhrensteinJoelle AsmarLaura WallaceAlicia W. Gilsenan
作者单位: 1RTI Health Solutions, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain
2Research Triangle Park, North Carolina, NC, USA
3PHARMO Institute for Drug Outcomes Research, Van Deventerlaan 30-40 3528 AE, Utrecht, Netherlands
4Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark
5IQVIA, RWI, Tour D2, 17 Bis Place des Reflets, TSA 64567, 92099, La Défense Cedex, France
6Boehringer Ingelheim International GmbH, Binger Str. 173, 55216, Ingelheim am Rhein, Germany
7Boehringer Ingelheim International GmbH, 900 Ridgebury Road, 06877, Ridgefield, CT, USA
刊名: Scientific Reports, 2020, Vol.10 (1), pp.1169-1171
来源数据库: Springer Nature Journal
DOI: 10.1038/s41598-019-57397-5
英文摘要: Abstract(#br)To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Netherlands, the Danish population registers, and the IMS Real-World Evidence Longitudinal Patient Database panels in France. On-label use was defined as use among adults with a recorded diagnosis of COPD. Off-label use was defined as use among adults with a recorded diagnosis of asthma without a recorded diagnosis of COPD or as use among patients aged ≤18 years. Potential off-label use was defined as no recorded diagnosis of either COPD or asthma. The study included 4,158 new users of olodaterol and 9,966 new users of indacaterol....
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.927 (2012)

×